Abstract
Chemotherapeutic drugs for cancer treatment have been traditionally originated by the isolation of natural products from differet environmental niches, by chemical synthesis or by a combination of both approaches thus generating semisynthetic drugs. In the last years, a number of gene clusters from several antitumor biosynthetic pathways, mainly produced by actinomycetes and belonging to the polyketides family, are being characterized. Genetic manipulation of these antitumor biosynthetic pathways will offer in the near future an alternative for the generation of novel antitumor derivatives and thus complementing current methods for obtaining novel anticancer drugs. Novel antitumor derivatives have been produced by targetted gene disruption and heterologous expression of single (or a few) gene(s) in another hosts or by combining genes from different, but structurally related, biosynthetic pathways (“combinatorial biosynthesis”). These strategies take advantage from the “relaxed substrate specificity” that characterize secondary metabolism enzymes.
Keywords: Anticancer Drugs, antitumor, heterologous, actinomycetes, polyketides
Combinatorial Chemistry & High Throughput Screening
Title: On the Generation of Novel Anticancer Drugs by Recombinant DNA Technology: The Use of Combinatorial Biosynthesis to Produce Novel Drugs
Volume: 6 Issue: 6
Author(s): Carmen Mendez and Jose A. Salas
Affiliation:
Keywords: Anticancer Drugs, antitumor, heterologous, actinomycetes, polyketides
Abstract: Chemotherapeutic drugs for cancer treatment have been traditionally originated by the isolation of natural products from differet environmental niches, by chemical synthesis or by a combination of both approaches thus generating semisynthetic drugs. In the last years, a number of gene clusters from several antitumor biosynthetic pathways, mainly produced by actinomycetes and belonging to the polyketides family, are being characterized. Genetic manipulation of these antitumor biosynthetic pathways will offer in the near future an alternative for the generation of novel antitumor derivatives and thus complementing current methods for obtaining novel anticancer drugs. Novel antitumor derivatives have been produced by targetted gene disruption and heterologous expression of single (or a few) gene(s) in another hosts or by combining genes from different, but structurally related, biosynthetic pathways (“combinatorial biosynthesis”). These strategies take advantage from the “relaxed substrate specificity” that characterize secondary metabolism enzymes.
Export Options
About this article
Cite this article as:
Mendez Carmen and Salas A. Jose, On the Generation of Novel Anticancer Drugs by Recombinant DNA Technology: The Use of Combinatorial Biosynthesis to Produce Novel Drugs, Combinatorial Chemistry & High Throughput Screening 2003; 6 (6) . https://dx.doi.org/10.2174/138620703106298699
DOI https://dx.doi.org/10.2174/138620703106298699 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Growth Factors in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design HTLV-1 Associated Neurological Disorders
Current Topics in Medicinal Chemistry Glioblastoma Tumor Initiating Cells: Therapeutic Strategies Targeting Apoptosis and MicroRNA Pathways
Current Molecular Medicine Rhein Derivatives, A Promising Pivot?
Mini-Reviews in Medicinal Chemistry Surface Plasmon Resonance Imaging Sensor for Cathepsin Determination Based on Immobilized Cystatin
Protein & Peptide Letters G-Quadruplex Interacting Agents Targeting the Telomeric G-Overhang Are More than Simple Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Progress in the Development of Bestatin Analogues as Aminopeptidases Inhibitors
Current Medicinal Chemistry Intracellular Restriction Factors In Mammalian Cells - An Ancient Defense System Finds A Modern Foe
Current HIV Research Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Vasoproliferation and Antiproliferative Treatment Options in Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery The Role of Maternal Serum Biomarkers in the Early Diagnosis of Ectopic Pregnancy
Current Chemical Biology New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Coordinated Expression of Pax-5 and FAK1 in Metastasis
Anti-Cancer Agents in Medicinal Chemistry An Overview of Innovations in Analysis and Beneficial Health Effects of Wine Polyphenols
Mini-Reviews in Medicinal Chemistry The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Carbon Nanotubes: Classification, Method of Preparation and Pharmaceutical Application
Current Drug Delivery Pulmonary Arterial Hypertension
Current Vascular Pharmacology Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Synergy Against Fungal Pathogens: Working Together is Better Than Working Alone
Current Medicinal Chemistry